Acinetobacter baumannii infections: Global Phase 3 ATTACK trial of Sulbactam-Durlobactam
by Press Release from Outbreak News Today on (#53M44)
By NewsDesk @infectiousdiseasenews Commercial stage biopharmaceutical company, Zai Lab Limited, announced today dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter baumannii infections. With over 200,000 occurrences estimated each year, China ranks among [...]
The post Acinetobacter baumannii infections: Global Phase 3 ATTACK trial of Sulbactam-Durlobactam appeared first on Outbreak News Today.